Elon Musk and his Neuralink company's attempt to begin testing brain chips in humans has been rejected by the FDA, according to a report by Reuters.
The request was submitted to the agency last year but according to Reuters, the FDA identified several problematic factors with the technology, including the chip's lithium battery and the potential for small wires to move to other areas of the brain.
"Neuralink doesn't appear to have the mindset and experience that's needed to get this to market anytime soon," Kip Ludwig, former program director for neural engineering at the U.S. National Institute of Health.
There was also a concern of whether or not the chip could be removed without inflicting damage to brain tissue.
What Exactly Is Neuralink?
Musk has claimed the technology could be life-changing for people suffering from paralysis, enabling them to communicate and walk, or it could help repair visual impairment in people.
The chip is supposed to process brain signals that are then transmitted to a device. While human trials for Neuralink have not commenced, there have been versions of the tech that reportedly had some success in animals. However, the company faced pushback and a probe from the U.S. Department of Agriculture after animal cruelty concerns were raised.
Last month Neuralink admitted that at least one monkey was euthanized because of a surgical complication.
Chris Marquette of POLITICO breaks down how the FAA is cutting flights and facing a critical shortage of air‑traffic controllers amid the government shutdown.
Dr. Manuele Aufiero, CEO & Co‑Founder of Sizable En a groundbreaking undersea energy‑storage technology powering the global shift to clean, scalable power.
Paul Fipps, President of Global Customer Operations at ServiceNow, breaks down the company’s earnings beat, 5‑for‑1 stock split and booming enterprise AI demand
Movie studios are comfortable digging through comic bins for hot new intellectual property, but they are not comfortable returning the favor and sharing th
Chris Versace, CIO at Tematica Research and portfolio manager for TheStreet Pro, joins from the NYSE to break down the Fed’s latest move and Big Tech’s earnings
Sabrina Siddiqui, National Politics Reporter at The Wall Street Journal, joins to break down the SNAP funding delays and the human cost of the ongoing shutdown.
Arguments at the Supreme Court have concluded for the day as the justices consider President Donald Trump's sweeping unilateral tariffs in a trillion-dollar test of executive power.
